With regards to today’s focus on a phase 2 randomised controlled trial (RCT), it is an intriguing development to be thinking about because usually it is phase 3 trials which tend to be rather controversial and generate a lot of reader questions. This especially true when it’s a negative study and people want to know why, or what on earth happened?!
It’s rare for a positive phase 2 trial to lead to more questions than any other studies being presented at a given cancer conference.
I must admit this was probably my favourite data of the ESMO meeting because it offers plenty of possibilities and also broader encouragement for the field when you consider how many studies have tried to manipulate the tumour microenvironment and not succeeded.
Between the current readout and the forthcoming pivotal phase 3 trial, however, lie a number of key questions which need to be addressed, as well as plenty of subtleties and nuance to think about carefully.
So what’s in store on the lung cancer front?